Introduction: The goal of treatment in diabetes is to control hyperglycemia to near-normal glucose levels, which is important to prevent the progression of microvascular and Results: A total of 136 patients with T2DM were eligible for enrollment in this study and received mitiglinide. The average HbA1c before the start of mitiglinide administration (baseline) was 7.47% in the DPP-4 inhibitor combined treatment group (DPP-4 inhibitor CTG) and 7.50% in the biguanide combined treatment group (biguanide CTG), and the 2 h PPG was 248.1 and 243.3 mg/dL, respectively. Following the addition of mitiglinide to the treatment regimen for 52 weeks, the early ClinicalTrials.gov identifier: NCT01333592. Electronic supplementary material The online version of this article (postprandial decrease in insulin secretion improved and PPG improved in both the DPP-4 inhibitor CTG and biguanide CTG. At final evaluation, the HbA1c \7.0% achievement rate was 57.4% in the DPP-4 inhibitor CTG and 29.2% in the biguanide CTG. The incidence of hypoglycemia in the DPP-4 inhibitor CTG and biguanide CTG was 3.0% (2/67 patients) and 2.9% (2/69 patients), respectively. The hypoglycemic symptoms were mild in all cases. Conclusion: Combination therapy with mitiglinide and DPP-4 inhibitors or biguanides improved glycemic control over the long term
macrovascular complications. Mitiglinide is a rapid-and short-acting insulinotropic sulfonylurea receptor ligand that is known to improve postprandial hyperglycemia in patients with type 2 diabetes. The aim of this study was to investigate the long-term efficacy and safety of mitiglinide in Japanese type 2 diabetic patients inadequately controlled by dipeptidyl peptidase-4 (DPP-4) inhibitor or biguanide monotherapy.
Methods: In patients with type 2 diabetes mellitus (T2DM) receiving a stable monotherapy regimen with a DPP-4 inhibitor or biguanide added to dietary therapy, an additional 10 mg mitiglinide was administered for 52 weeks. The efficacy end points were postprandial plasma glucose (PPG) (30 min, 1 h, 2 h), postprandial insulin (30 min, 1 h, 2 h), insulinogenic index, 1,5-anhydroglucitol (1,5-AG), glycated hemoglobin (HbA1c), and fasting plasma glucose. The safety end points included the incidence and types of adverse events and adverse drug reactions.
INTRODUCTION
Diabetes mellitus is characterized by chronic hyperglycemia and other metabolic abnormalities due to insufficient action of insulin. Diabetes is classified as type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) based on its etiology. The pathogenesis of T2DM involves a combination of impaired insulin secretion from pancreatic b cells and insulin resistance. Hyperglycemia develops from this insulin-insufficient state, often presenting early as postprandial hyperglycemia.
The goal of treatment in diabetes is to control hyperglycemia to near-normal glucose levels. This is important to prevent progression to microvascular complications, as well as to macrovascular complications such as myocardial infarction. Postprandial hyperglycemia has recently been reported to be an independent risk factor for arteriosclerotic disease [1] . The Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE) study reported a positive correlation between 2 h values on an oral glucose tolerance test (OGTT) and overall mortality rates [2] . The Funagata study, conducted among residents of Funagata in Yamagata Prefecture, reported that impaired fasting glucose (IFG), defined as an elevation of fasting plasma glucose (FPG), but with a normal 2 h OGTT value, was not a risk factor for cardiovascular death [3] . Large-scale clinical studies, including the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study [4] , the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study [5] and the Veterans Affairs Diabetes Trial (VADT) [6] , showed that glycemic control based on glycated hemoglobin (HbA1c) levels alone does not reduce macrovascular disease. In addition to glycemic control using HbA1c as a marker, high-quality glycemic control focusing also on postprandial plasma glucose (PPG) levels is necessary.
Mitiglinide is a rapid-and short-acting insulinotropic sulfonylurea receptor (SUR) ligand, a benzylsuccinic acid derivative [7] [8] [9] , which improves postprandial hyperglycemia in particular.
In addition to mitiglinide, repaglinide and nateglinide are currently in clinical use as insulinotropic SUR ligands. The presence or absence of adverse events and adverse drug reactions (all and hypoglycemia) was assessed in each patient, and the incidence and two-sided 95% confidence intervals were calculated. The incidence and types of adverse events and adverse drug reactions overall and by organ system class were calculated. Totals were calculated for each combined treatment group. Treatment was discontinued in 26 patients (DPP-4 inhibitor CTG, 9; biguanide CTG, 17) during the study. The reasons for discontinuation from the study were as follows: for DPP-4 inhibitor CTG-adverse events in two patients, inadequate response in five, and other reason in three patients (''at request of patient,'' ''needed to discontinue baseline drug,'' and ''could not return for outpatient visit''); and for biguanide CTGadverse events were reported in 4 patients, inadequate response in 12, and other reason in 2 patients (''at request by patient'' in both). One patient in both of the DPP-4 inhibitor CTG and biguanide CTG had two reasons for discontinuation (adverse event and patient request).
MATERIALS AND METHODS

RESULTS
Analyzed Cases
Patient Characteristics
A total of 136 patients received mitiglinide (DPP-4 inhibitor CTG, 67; biguanide CTG, 69), but after mitiglinide was started, one patient in the biguanide CTG was excluded because of early discontinuation and no evaluable HbA1c. Subsequently, in both cohorts there was a deterioration, followed by a trend toward improvement from week 40 until completion of mitiglinide administration (data not shown).
In both the DPP-4 inhibitor CTG and biguanide CTG, postprandial insulin levels at each evaluation time point confirmed significant stimulation of insulin secretion at 30 min and 1 h postprandially (Fig. 2) . Fasting insulin levels did not substantially change throughout the study period. Table 3 shows the changes in HbA1c. Table 4 shows the HbA1c \7.0% achievement rates at Adverse events with an incidence C5% in the DPP-4 inhibitor CTG included nasopharyngitis, 25.4% (17/67); pharyngitis, 9.0% (6/67); upper respiratory tract infection, 7.5% (5/67); arthralgia, 6.0% (4/67); back pain, 6.0% (4/67); and c-glutamyltransferase increase, 6.0% (4/67). Adverse events with an incidence C5% in the biguanide CTG included nasopharyngitis, 43.5% (30/69); bronchitis, 11.6% (8/69); c-glutamyltransferase increase 10.1% (7/69); upper respiratory tract infection, 7.2% (5/69) alanine aminotransferase increase, 7.2% (5/69); white blood cell count increase, 7.2% (5/69); dental caries, 5.8% (4/69); and blood urine presence, 5.8% (4/69) ( Table 6 ).
The number of adverse events by severity was: DPP-4 inhibitor CTG-mild 128, moderate 5, and severe 0 events; biguanide CTG-mild 185, moderate 5, and severe 6 events. Most adverse events were mild or moderate. A causal relationship with mitiglinide was excluded for all the six severe events in the biguanide CTG.
In addition, all hypoglycemic events were mild.
One serious adverse event occurred in one patient in the DPP-4 inhibitor CTG: large intestine carcinoma. Nine serious adverse events occurred among five patients in the biguanide CTG: prostate cancer, acute myocardial infarction, brain contusion, skull fracture, traumatic lung injury, rib fracture, lumbar vertebral fracture, colonic polyp, and large intestine carcinoma. A causal relationship with mitiglinide was excluded for all of these serious adverse events. No deaths occurred in the study. completion tended to return to baseline levels.
Blood pressure showed no significant changes in either the DPP-4 inhibitor CTG or biguanide CTG.
DISCUSSION
Mitiglinide, a rapid-and short-acting insulinotropic agent, has been used to improve postprandial hyperglycemia in T2DM [11] [12] [13] . However, to date, sufficient evidence has not been established for combined treatment with a DPP-4 inhibitor or biguanide. In this study, we investigated the efficacy and safety of mitiglinide for use in combined treatment in Japanese patients with T2DM experiencing inadequate glycemic control with DPP-4 inhibitors or biguanides monotherapy.
With regard to efficacy, in both the DPP-4
inhibitor CTG and biguanide CTG, the addition of mitiglinide significantly stimulated early postprandial insulin secretion, with significant improvement in PPG (30 min, 1 h, and 2 h values) throughout the study period. In general, IGI is often B0.4 during a 75-g OGTT in T2DM patients [14] . In this study, the baseline IGI was as low as 0. Regarding HbA1c as a marker of overall glycemic control, an HbA1c of \7.0% has been established as a target in terms of preventing diabetic complications [14] . In this study, at the time of final evaluation, the HbA1c \7.0% In both the DPP-4 inhibitor CTG and biguanide CTG, HbA1c transiently increased after week 28, reached a peak at week 40, and then again improved. The reason was probably a seasonal fluctuation in HbA1c levels, as clinically reported in Japan and overseas [12] [13] [14] . These clinical reports have described increased HbA1c levels from the autumn to before spring, with fluctuations of about 0.2-0.3%. In this study, weeks 24-40 in many patients corresponded to the period from autumn to before spring. Considering that the increase in HbA1c was also about 0.2-0.3%, the fluctuation in this study was probably similar to the seasonal fluctuations reported elsewhere [15] [16] [17] . These findings again highlight the importance of not only drug therapy, but also dietary and exercise therapy in T2DM.
With regard to safety, the incidence of hypoglycemia, which is generally a concern when using oral glucose-lowering drugs, was 
CONCLUSION
The combination of mitiglinide with DPP-4 inhibitors or biguanides improved postprandial hyperglycemia and HbA1c, as a marker of overall glycemic control, without increasing risk to safety. This therapy is a clinically promising therapeutic strategy for T2DM.
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